Navigation Links
Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents

BURLINGTON, Mass., Aug. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that as the health technology assessment bar rises sharply across the EU5 (France, Germany, Italy, Spain and the United Kingdom), interviewed payers seek robust efficacy advantages over the right comparators and clear demonstration of potential for downstream cost savings in exchange for optimal reimbursement of type 2 diabetes therapies. As type 2 diabetes becomes increasingly prevalent in Western markets, the cost of related complications and comorbidities weighs heavily on tightening EU5 healthcare budgets. Payers report that novel agents that delay disease progression and show positive weight loss and cardiovascular outcomes data, ideally with detailed pharmacoeconomic analyses, will secure favorable market access conditions long term.

(Logo: )

The new European Physician and Payer Forum report entitled Market Access Challenges Facing Newly Launched and Emerging Type 2 Diabetes Agents in the EU5: Physician Prescribing Perspectives and Payer Insights finds that at least three-quarters of surveyed EU5 endocrinologists, diabetologists and general practitioners (GPs) believe that, despite market crowding, unmet need remains for the DPP-IV inhibitor drug class, while at least two-thirds think likewise for the GLP-1 receptor agonists. Key unmet needs highlighted for the DPP-IV inhibitors include better reduction in HbA1c, and confirmation of disease-modifying effect, while—in addition to injection-free administration—positive cardiovascular outcomes data emerges as a primary preference for the GLP-1 analogues. Agents targeting these unmet needs should also help to address payer demands for downstream cost-savings, thus encouraging budget holders at all levels to think beyond the price tag as competition heightens among type 2 diabetes drug classes.    

However, the report also finds that as manufacturers strive for optimal pricing and reimbursement terms amid stringent HTA demands, they must be careful not to price themselves out of the market if they want to secure maximum uptake of their brands. Price must be carefully balanced with uptake potential for optimal return on investment.

"One quarter of surveyed GPs in Germany do not currently prescribe GLP-1 analogues to more than half of their eligible type 2 diabetes patients due to the constraints of their indicative prescribing budgets, while around two thirds of survey respondents in Spain report that their ability to prescribe DPP-IV inhibitors and GLP-1 analogues is at least somewhat impacted by recently increased patient copay," said Decision Resources Senior Director Janie Cox, Ph.D. "As the EU5 countries continue to feel the force of the economic crisis, industry is challenged with maximizing profitability at competitive rather than premium prices."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
3. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
4. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
5. Optimization of Comparative Efficacy Trials
6. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
11. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: ) , ... , TwinLink™ - the first dual communication ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):